Evaluating the Maintenance of Efficacy and Tolerability of Transitioning from IV Anti-CD20 Therapy to Ublituximab: ENHANCE Study Interim Data

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
Drug Category: Array
Conference Category: Array
Lead Author: Singer B, et al.
Published Date: 29/02/2024
Download Link: /wp-content/uploads/2024/02/P109_Singer.pdf
Download Text:
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top